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Abstract
It has been shown that prolonged systemic presence of a drug can cause a build up of that drug
in the skin. This drug ’reservoir’, if properly understood, could provide useful and important
information about recent drug-taking history of the patient. In this paper we create a pair of
coupled mathematical models which combine together to explore the potential for a drug reservoir
to be created based on the kinetic properties of the drug. The first compartmental model is used
to characterise time-dependent drug concentrations in plasma and tissue following a customisable
drug regimen. Outputs from this model provide boundary conditions for the second, spatio-temporal
model of drug build-up and concentration profile in the skin.
We focus in particular on drugs that are highly bound as this will restrict their potential to move
freely into the skin but which are lipophilic so that, in the unbound form, they would demonstrate
an affinity to the outer layers of the skin (which are built around a lipid matrix). Buprenorphine,
a drug used to treat opiate addiction, is one example of a drug satisfying these properties. In the
discussion we highlight how our study might be used to inform future experimental design and
data collection to provide relevant parameter estimates for reservoir formation and its potential to
contribute to enhanced drug monitoring techniques.
Keywords: Skin, drug reservoir, binding, non-invasive drug monitoring, lipophilic, mathematical
modelling.
1. Introduction
The reservoir function of the skin is a recognised phenomena in the field of percutaneous absorp-
tion [1]. A reservoir in the skin was first identified for the case of topically applied corticosteroids
[2, 3] after a prolonged therapeutic effect was observed. Presence of a reservoir in the skin has since
been demonstrated for many other drugs [1]. Moreover it has been shown, via tape stripping, that
the main site of this skin reservoir is the stratum corneum (SC), the layer of dead cells at the skin
surface [1, 2, 4].
Research on the presence of a reservoir in the SC is generally focussed on formation from an
external source, specifically topically applied drugs and chemical exposure [1]; drug that comes
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into contact with the skin surface enters the body via passive diffusion. As only unbound drug
diffuses [5] the cause of a reservoir forming in the SC is thought to be high keratin binding and
slow desorption kinetics [5]. Binding within the skin is most typical for lipophilic drugs with high
molecular weight [6, 7].
More recently, detection of a ‘reservoir’ of drug in the skin as a result of systemic presence of
that drug has highlighted the potential of skin to act as a site for noninvasive monitoring [8] both
to measure systemic drug levels and to estimate historic usage by exploiting the reservoir.
The existence of such a reservoir in the SC has been demonstrated in the case of lithium
[8, 9]. Lithium is a small drug which remains unbound and is not metabolised within the body.
Mathematical modelling in that case [10], showed how the drug reservoir could be used to assess
prescription compliance; but it was a simplest case scenario in many ways given the properties of
the drug within the body.
The purpose of this paper is to extend that work to use a mathematical modelling approach
to explore the potential for reservoir formation with a more complex drug. In particular, we are
interested in a drug that is metabolised within the body; bound to molecules within the body; and
lipophilic. These choices reflect the properties of many prescription drugs that are metabolised
as well as excreted by the body and which bind to proteins and other molecules within both the
plasma and the tissue. The choice of a lipophilic drug reflects the composition of the SC which
consists of a lipid matrix together with corneocytes and their connecting structures, desmosomes;
by focussing on a drug that is lipophilic, we assume that the drug will have affinity to the SC and
potentially a tendency to accumulate in this outer skin layer. The drug buprenorphine used to treat
opiate addiction, where compliance is an essential component of effective treatment, satisfies these
three criteria and so acts as a motivation for our choice. Despite being well-established, parameter
estimates for buprenorphine in the mechanistic model structure are not readily available from the
literature and so we use this example simply as a motivation at this stage for our theoretical
modelling work.
Classical modelling approaches to drug absorption, distribution, metabolism and excretion
(ADME processes) often use a phenomenological approach in which model compartments rep-
resent theoretical spaces to give model predictions that fit well with the data. These are known as
pharmacokinetic models. More recently, there has been a move towards more complicated phys-
iologically based pharmacokinetic models (PBPK) which take a mechanistic approach, modelling
each component of the body relevant to the passage of a given drug [11]. PBPK models are used as
predictive tools in research, drug development and risk assessment. However, these models require
large amounts of data to estimate the considerable number of model parameters.
In the following section we build the model structure which consists of two sub-models that
couple together to provide a profile of compartmental drug concentrations in the body and spatial
distribution within the SC. The compartmental body model is a simplified form of a PBPK model
where we restrict the number of body compartments to three, invoking Occams razor. The outputs
from this model provide boundary conditions for the spatial distribution model in the SC. Analysis
of the models leads to predictions about the effect of bound and unbound plasma drug concentration,
drug compliance, binding coefficients and diffusive potential on reservoir size. We conclude with
observations about the potential to exploit the SC reservoir as a mechanism for non-invasive drug
monitoring.
2
2. Model
The mathematical model is built in two stages: firstly, a compartmental system of coupled ODEs
is used to model time-dependent drug concentrations within the body in response to a regularly
administered drug. The outputs from this model provide boundary conditions for the second stage
model which explores the spatial distribution of drug molecules within the SC; in turn, this is used
to calculate the total amount of drug (the reservoir) within the SC as a function of key, critical
parameters. It should be noted that whilst Model 1 feeds into Model 2, the converse is not true.
We assume that any drug which enters the SC is not reabsorbed into the blood. We assume that
active drug is administered and it is the administered drug that we are interested in modelling. A
single daily dose is administered in the fully compliant case. For simplicity we will not consider
drug-drug interactions.
2.1. Model 1
This model comprises six time-dependent state variables: unbound drug molar concentration
in plasma, Pu(t); bound drug concentration in plasma, Pb(t); unbound drug concentration in well
perfused tissues, Qu(t); bound drug concentration in well perfused tissues, Qb(t);unbound drug
concentration in poorly perfused tissues, Ru(t) and bound drug concentration in poorly perfused
tissues, Rb(t) at time t. Noting that only unbound drug is able to move between plasma and tissue,
we create a mathematical model based on the schematic shown in Figure 1. The model equations
are built from conservation principles on the amount of drug in the system. For unbound drug in
the plasma we have:
Change in amount of unbound drug in plasma (over time)
=− net binding of drug to plasma proteins
− net movement of drug into well perfused tissues
− net movement of drug into poorly perfused tissues
− drug metabolised and excreted
+ administered drug.
(1)
As we are considering a fixed plasma volume, Vp, the amount of drug in the plasma is Pu(t)Vp.
(Net) Binding. Binding in the plasma is a reversible process where, at equilibrium, unbound drug
will be a fraction, fup, of the total drug in the plasma, (Pu+Pb). We assume that the rate at which
this equilibrium is approached is directly proportional to the difference between the amount of
unbound drug at time t, Pu(t), and the amount that will be unbound at equilibrium, fup(Pu +Pb).
This gives rise to a binding rate
−k1(Pu − fup(Pu + Pb)),
where k1 is a positive rate constant. The effect of this term on the amount of unbound drug will
be positive if Pu is below its equilibrium level and negative if above.
(Net) Movement Into Tissue. Again, this process is reversible. Only unbound drug moves between
plasma and tissue which we exploit to give the rate of movement into tissue from the plasma as
−k2(Pu − f2Qu)− k3(Pu − f3Ru).
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Figure 1: Schematic demonstrating the flow of drug within a simplified body compartmental structure. Parameters
ki (i = 1...6) are described in the text.
The parameters k2, k3 are the rates at which movement occurs and are dependent on a number of
variables such as blood flow to tissues and partitioning coefficients.
Tissues are assigned to well perfused or poorly perfused tissue compartments according to blood
perfusion values given in [12]. It therefore follows that k2 > k3. The remaining two parameters,
f2 and f3 represent the ratio between concentration of drug in plasma and well perfused tissue,
and plasma and poorly perfused tissue at equilibrium respectively. According to the allocation of
tissues to each compartment, poorly perfused tissues have a much higher fat percentage than well
perfused tissues [12]. As we are considering lipophilic drugs we can also expect f2 > f3 (higher
affinity for fatty tissue).
Metabolism. Metabolism is described by Michaelis Menten kinetics. Only unbound drug in the
plasma is metabolised. Hence we obtain the rate of metabolism:
VmaxPu
km + Pu
,
where Vmax and km are the maximum velocity and michaelis constant respectively.
Multiple Dose. The term describing administration of drug is of the form
N∑
i=1
δk exp(−k(t− Ti))
4
as used in the model by Paulley et al [10] for a repeat lithium dose. For simplicity, on administration,
dose is assumed to be distributed homogeneously in the plasma. The parameter δ is the ‘size’ of
the dose that arrives in the body, calculated as the mass of dose × bioavailability and converted
to molar concentration by dividing through by molar mass and plasma volume. The dissolution/
absorption rate constant for the given route of administration is given by k, which reflects that
drug not given intravenously will not all arrive in the body immediately. Doses are administered
at the times Ti where N is the number of doses administered [10, 13].
Combining these terms with (1) gives rise to the model equation
dPu
dt
=− k1(Pu − fup(Pu + Pb))− k2(Pu − f2Qu)− k3(Pu − f3Ru)
− VmaxPu
km + Pu
− k4Pu +
N∑
i=1
δk exp(−k(t− Ti)),
where parameters and variables are defined as in Table B.1 (see appendix).
Note that
∫ inf
Ti
δk exp(−k(t− Ti))dt = δ which means that the full dose δ does eventually reach the
plasma.
Volume Adjustment Between Compartments. We assume bound and unbound drug occupy the same
volume within compartments. We can not, however assume that volume between compartments
is the same. We introduce the dimensionless variables vQ/P =
vQ
vP
, vR/P = vRvP where vQ, vP and
vR are the volumes of Q, P , and R respecitvely. This ensures that the conservation of mass is
maintained as drug moves between compartments.
Combining all elements, we obtain the full model system:
dPu
dt
=− k1(Pu − fup(Pu + Pb))− k2(Pu − f2Qu)− k3(Pu − f3Ru),
− VmaxPu
km + Pu
− k4Pu +
N∑
i=1
δk exp(−k(t− Ti)), (2a)
dPb
dt
=k1(Pu − fup(Pu + Pb)), (2b)
dQu
dt
=k2vQ/P (Pu − f2Qu)− k5(Qu − fuQ(Qu +Qb)), (2c)
dQb
dt
=k5(Qu − fuQ(Qu +Qb)), (2d)
dRu
dt
=k3vR/P (Pu − f3Ru)− k6(Ru − fuR(Ru +Rb)), (2e)
dRb
dt
=k6(Ru − fuR(Ru +Rb)). (2f)
Using parameters described in Table B.1 (which are estimates for buprenorphine taken from the
literature) and assuming no drug in all compartments initially, we obtain concentration profiles as
shown in Figure 2 we use this profile as input to Model 2 where drug accumulates in the stratum
corneum.
5
0 24 48 72 96 120 144 168 192 216 240 264 288 312
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0.04
Time/ hours
C
o
n
ce
n
tr
a
ti
o
n
µ
m
o
l/
L
 
 
Total buprenorphine in plasma
Total buprenorphine in well perfused tissues
Total buprenorphine in poorly perfused tissues
Figure 2: Simulation of plasma and tissue concentration profiles for a daily drug administration, using model 2 with
parameter values as given in Table B.1.
2.2. Model 2
In this section we obtain a description of the formation of a drug reservoir in the stratum
corneum (SC). Our hypothesis is that drug builds up in the SC to create a reservoir where inflow
from poorly perfused tissues is balanced by a loss from skin surface.
Drug Binding in Skin. In model 1, we considered bound and unbound drug in the plasma and
tissues. Drug binds to keratin in the skin [7] and the dynamics of binding in the skin have been
shown to be linear [14]. As only unbound drug is free to diffuse [5], binding may be an important
factor in the formation of a SC reservoir. We therefore consider both bound and unbound drug in
the SC and allow for the possibility of binding and unbinding.
Passive Diffusion Through the Skin. Movement of drug into the skin occurs via passive diffusion
down concentration gradients and is described by Fick’s law of diffusion assuming a constant diffu-
sion coefficient, D > 0.
Movement with the Differentiating Cells. Cells and intercellular material in the skin move from the
viable epidermis to the skin surface where they are shed [15, 16]. This movement is often neglected
in delivery studies as the timescale under consideration is usually too short. However Simon et al
included the effects of epidermal turnover in their mathematical drug delivery model [17]; in that
case the epidermal turnover opposed movement of the drug into the SC from the skin surface. In
this case we are considering the movement of drug from the base of the SC to the skin surface
i.e. with the direction of movement of renewing cells. Epidermal turnover and desquamation is
affected by many variables including hydration, time of day and skin condition. Here we focus on
the underlying mechanism and assume that the skin moves towards the body surface at constant
velocity v > 0.
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Figure 3: Schematic for model 2 where SC is the stratum corneum and VE is the viable epidermis represented by
‘poorly perfused tissues’ from model 1. Dotted arrows denote diffusion of unbound drug and dashed arrows denote
convective movement of bound and unbound drug due to the renewal of the stratum corneum at rate v.
Model Assumptions. We consider a one-dimensional spatial domain for the SC since we assume
that the drug is distributed homogeneously across the viable epidermis (VE), the layer below the
SC. In this case x = 0 corresponds to the boundary between the SC and VE and x = L corresponds
to the surface of the skin.
We let Cu(x, t) and Cb(x, t) denote the concentration of unbound and bound drug at x at time t
respectively and develop a diffusion-convection model based on the schematic shown in Figure (3)
assuming that
1. Unbound drug diffuses across the SC with diffusion coefficient D > 0.
2. Bound and unbound drug move towards the surface of the skin at constant velocity v > 0
corresponding to the cell renewal in the SC.
3. Bound drug becomes unbound at the rate µ > 0 and unbound drug becomes bound at rate
γ > 0.
4. At x = 0, concentration of bound and unbound drug corresponds to those values obtained
from the poorly perfused tissue in the compartmental model, Rb(t), Ru(t) respectively.
5. At x = L, we assume no diffusion across the surface of the skin.
Combining these elements we obtain the model system:
∂Cu
∂t
=D
∂2Cu
∂x2
− v ∂Cu
∂x
+ µCb − γCu, (3a)
∂Cb
∂t
=− v ∂Cb
∂x
− µCb + γCu. (3b)
At x = 0, the interface between the stratum corneum and viable epidermis, the boundary conditions
are
Cu(0, t) =αRu(t), (4a)
Cb(0, t) =αRb(t), (4b)
(4c)
7
where α reflects a change in volume between poorly perfused tissues and the SC and where Ru(t)
and Rb(t) are outputs from model 1. Boundary conditions at the surface are given by
D
dCu
dx
∣∣∣∣
x=L
= 0 (no diffusion across skin surface). (5)
2.3. Calculation of Reservoir Size
We consider the size of the reservoir to be the amount of drug across the entire thickness of the
stratum corneum. If we consider constant boundary conditions αRu(t) = αR¯u, αRb(t) = αR¯b, we
can find an expression for the drug distribution in the SC at steady state by setting the LHS of (3)
equal to zero (for calculation see appendix Appendix A). This results in steady state distribution
in the SC given by.
C = av0 + bv+exp(λ+x) + cv−exp(λ−x), (6)
where a, b and c are constants, found using boundary conditions (4) to be
a =αR¯b − b− c, (7)
b =
(
αR¯u − αµR¯b
γ
− cvλ−
γ
)
γ
λ+v
, (8)
c =
α
(
γR¯u − µR¯b
) (
µ
v + λ+
)
exp(λ+L)
λ−[(exp(λ+L)(µ+ λ+v)− exp(λ−L)(µ+ λ−v)] . (9)
We use these distributions to explore the form and size of drug reservoir in the skin.
Note that if we consider binding and unbinding occurring at an equal rate (µ = γ) and constant
boundary conditions with equal concentrations of bound and unbound drug (αRu = αRb) then
from equations (7-9) c=0 and so b=0 giving a=αRb. Using this in (6) the steady state solution of
drug in the SC for equal binding and unbinding rates and equal bound and unbound drug on the
boundary is
C = αRu

1
1
0
 (10)
i.e. we expect no spatial dependence in the steady state reservoir concentration. The reservoir size
per unit surface area of the skin is given as
Su = αRuL = Sb. (11)
2.4. Reservoir Size
The size of the unbound and bound reservoir (Su, Sb) at steady state can be found by integrating
the steady state solution over x between 0 and L which gives:
Su =
∫ L
0
Cu(x)dx =
aµL
γ
+ b
(
µ+ λ+v
γλ+
)
(exp(λ+L)− 1) + c
(
µ+ λ−v
γλ−
)
(exp(λ−L)− 1) , (12)
Sb =
∫ L
0
Cb(x)dx = aL+
b
λ+
(exp(λ+L)− 1)− c
λ−
(exp(λ−L)− 1) , (13)
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where a, b, c are constants (7-9) and
λ+ =
v
D
− µ
v
+
√(
− v
D
+
µ
v
)2
+ 4
( µ
D
+
γ
D
)
2
, (14)
λ− =
v
D
− µ
v
−
√(
− v
D
+
µ
v
)2
+ 4
( µ
D
+
γ
D
)
2
. (15)
We use these expressions to explore how changes in model parameters affect reservoir size.
2.5. Parameter Values Used in Numerics
The thickness of the SC (L) is dependent on many variables including region of the body, age,
gender and health. In a study by Sandby et al [18] the average thickness of the SC for the forearm,
where measurements are usually taken, is given as 18.3µm and it is this value chosen for L in
numerical simulations.
The time taken to renew the SC is typically taken to be 14 days for a healthy adult [19, 20, 16],
we therefore take v to be 0.054µmh−1.
Values of D,µ and γ are drug dependent and are often uncertain or unknown. Boundary values
αRu and αRb come from the first model and are consequently variable and depend on drug intake.
We therefore explore the dependence of our reservoir size on these unknown parameters.
3. Results
3.1. Dependence of Reservoir Size on Binding
The importance of binding parameters in transdermal drug delivery has been highlighted re-
cently in a paper by Pontrelli and de Monte [21]. A comparison between reservoir size and diffusion
coefficient, D, for different binding rates with different bound/unbound ratios at the boundary is
given in Figure 4. From this we can see that for sufficiently large D reservoir size approaches a
constant value dependent on the boundary conditions and binding rates. The relative proportion
of bound to unbound drug in the reservoir at steady state appears to be controlled by the bind-
ing rates, γ and µ, whereas the scale of the reservoir is affected by a combination of the ratio of
bound/unbound drug at the boundary and the rates of binding, γ, and unbinding, µ in the SC.
Next we explore how the reservoir size depends on the binding and unbinding rates whilst
keeping D fixed and boundary conditions constant. In Figure 5(a) we vary γ and observe that
the total reservoir size increases essentially linearly with γ, driven by an increase in the amount of
bound drug. Variation in γ has no effect on the amount of unbound drug in the reservoir at steady
state (due to the non-zero value of D). In Figure 5(b), we vary µ and in this case observe that the
total reservoir size is inversely proportional to µ, again driven by a similar relation between bound
drug and µ. From both graphs we see that binding mechanisms of drug within the SC may prove
a crucial factor in expected reservoir size. Moreover the comparative levels of bound and unbound
drug may be significant when considering extraction of the reservoir. If, for example, only unbound
drug is retrieved with a given extraction method, high binding and low unbinding may decrease
rather than increase observed reservoir size.
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Figure 4: Steady state reservoir size plotted against D for the cases µ > γ with (a) even (αRu = αRb = 1) and
(b) uneven (αRu = 0.08, αRb = 1.92) binding on the constant boundary at x=0 and for the case µ < γ with (c)
even (αRu = αRb = 1) and (d) uneven (αRu = 0.08, αRb = 1.92) binding on the constant boundary at x = 0. As
parameter values chosen here are for qualitative exploration, units of reservoir size have been omitted.
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Figure 5: Steady state reservoir size plotted against (a) binding rate, γ with constant µ = 1 and (b) unbinding rate
µ, with constant γ = 1 both graphs plotted using constant diffusion, D = 0.5 and constant boundary conditions at
x = 0, αRu = αRb = 1. As parameter values chosen are for qualitative exploration, units of reservoir size have been
omitted.
3.2. Dependence of Reservoir Size on Boundary Drug Distribution
In Figure 6 we show how the binding ratio for drug in the poorly perfused tissue (Figure 2)
impacts on reservoir size. From this figure we note that; in all cases, as the percentage of drug
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that is unbound increases in body, the reservoir size increases and when the rate of binding exceeds
the rate of unbinding in the SC, the reservoir size is significantly larger than when this relation is
reversed. Again this has relevance for the extraction process as detailed above in 3.1.
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Figure 6: Steady state reservoir size plotted against % of drug unbound on boundary x = 0 for constant total
boundary condition αRu +αRb=2 for (a) µ > γ (b) µ = γ (c) µ < γ. As parameter values chosen are for qualitative
exploration, units of reservoir size have been omitted.
3.3. Time to Form Reservoir
Whilst steady state reservoir size provides valuable information about the scale of the drug
storage in the skin, it does not provide any information on how long it takes for the reservoir to
form. This is an important measure as it indicates how sensitive the reservoir size is to a change in
boundary condition and therefore how quickly it will reflect a change in dose.
In the case where the rate of unbinding is greater than the rate of binding (µ > γ), illustrated
by Figures 7(a) and 7(b), the time taken to reach steady state decreases with an increase in D, i.e.
the faster the diffusion of unbound drug, the quicker the reservoir is to settle to its steady state
level. For small D the accumulation of the reservoir is initially slower than for large D but over
time this reverses. This is because initially, greater diffusion allows unbound drug to access the
whole region before becoming bound and so the reservoir builds rapidly but as the unbound drug
spreads through the region, having smaller diffusion allows more drug to become bound and hence
the reservoir size increases.
In the case where the rate of binding is greater than the rate of unbinding (γ > µ), Figure 7(c),
7(d), the time taken to reach steady state increases with an increase in D. This is because in this
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Figure 7: Reservoir size plotted against time for diffusion coefficient D= 0.05, 0.5, 1 and 2 with constant boundary
conditions, αR¯u = αR¯b = 1 for a) unbound drug with unbinding rate (µ) > binding rate (γ), b)bound drug with
unbinding rate (µ) > binding rate (γ), c)unbound drug with unbinding rate (µ) < binding rate (γ), d)bound drug
with unbinding rate (µ) < binding rate (γ). As parameter values chosen are for qualitative exploration, units of
reservoir size have been omitted.
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Figure 8: a) Total reservoir size plotted against time for diffusion coefficient D= 0.05, 0.5, 1 and 2 with constant
boundary conditions, αR¯u = αR¯b = 1 and equal binding and unbinding, µ = γ = 1. with a perturbation to the
boundary conditions at t=500h for 24 hours of αR¯u = αR¯b = 2. b) Enlarged view of Figure 8(a). As parameter
values chosen are for qualitative exploration, units of reservoir size have been omitted.
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case at steady state we expect more bound than unbound drug in the reservoir. The dominant
equation in this case is therefore (3b). When D is sufficiently small, the governing equation for
unbound drug (3a) is in agreement with the bound equation and both bound and unbound drug
move through the domain with the skin (v) allowing for local binding dynamics to settle quickly
and therefore reaching steady state quickly. However presence of diffusion in equation (3a) disrupts
the system, with larger D values causing a greater perturbation and therefore taking longer to reach
steady state.
In Figure 8(a) we show how quickly a perturbation to the drug concentrations at the boundary
affects the reservoir size, depending on the diffusion coefficient. To explore this behaviour µ, γ are
set to 1 so that the effect of differing binding rates does not influence our results and similarly we
take ¯αRu = ¯αRb = 1 so that drug concentrations at the boundary x = 0 are equal. In this figure, at
t = 500h a perturbation is applied at the boundary for 24 hours, we see that for larger values of D,
the effect of the perturbation is more pronounced than for small D values but that the time taken
to return to a steady reservoir size is much less for large diffusion coefficients than small diffusion
coefficients.
This will be of importance when considering a fluctuating boundary condition as we have in the
body (from Model 1). A larger D would result in a shorter time to steady state (i.e. equilibrating
with in body concentrations quickly) which means that the reservoir size would reflect changes
in body concentration more dramatically; meaning traces of a fluctuation will also be removed
more quickly. Whereas a smaller D would result in a reservoir that is less sensitive to in-body
concentration fluctuations.
Note that choices of γ and µ in the above figures are arbitrary. Figures shown are representative
of the cases where µ > γ and γ > µ and similar profiles were obtained for other choices of these
unknown parameters.
3.4. The Effect of Dose Compliance from Model 1 on Predicted Reservoir Size
Fluctuations in the boundary concentrations represent changes in systemic levels of drug which
in turn reflects a change in dose of drug and would ultimately indicate what level of noncompliance
would be observable in terms of reservoir size.
In the compliant case, with a daily dose of drug, Figure 9(a), we find that for a drug naive
patient, our model predicts a build up of drug in the SC over time which eventually levels off.
In the case of one missed dose at week five, figure 9(b), though the reduction in reservoir size is
evident in the time profile shown here, it is unlikely that such a small percentage change would be
observable experimentally, particularly at the low concentrations suggested here. Moreover, after a
week of taking the correct dose the level of drug in the skin is renewed and reaches similar levels
expected for a fully compliant scheme.
If we now consider habitual non compliance, demonstrated here as a single dose every other day,
figure 9(c), we see a notable reduction in reservoir size which reaches half the level of the compliant
case. This result is promising for potential compliance monitoring via the SC.
The time scales and values predicted rely on many uncertain parameter values for both in body
and in skin models. In order to get a better idea of how much drug reaches the SC and how quickly
the reservoir changes, more data are needed.
4. Conclusion
A two model system has been developed and analysed which describes the relationship between
a drug reservoir in the SC and drug concentration in the body. It follows work by Paulley et al
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Figure 9: Simulation of SC reservoir build-up of bound and unbound drug for a) a single daily dose for 6 weeks
in drug- naive patient, b) a single daily dose for 6 weeks with one missed dose at the begining of week 5 in drug-
naive patient, c) a single dose every other day for 6 weeks in drug- naive patient. Using ’poorly perfused tissue’
compartment from model 2 for systemic concentration as boundary conditions for SC model 3.
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[10] which used mathematical modelling to support observations that lithium reservoirs form when
drug is administered for chronic illness. The model presented here extends those ideas to the case
where the drug is found in both bound and unbound forms and in which the lipophilicity of the
drug are considered. Buprenorphine is used as an exemplar drug to populate some of the model
parameter values in numerical simulations.
Analysis has highlighted the importance of binding and unbinding in creating a reservoir of a size
that might reasonably be observed in the laboratory, this supports the findings by Pontrelli and de
Monte [21]. It has also provided insight into the time scales associated with reservoir formation and
response to in-body changes in drug concentration. The modelling highlights the need to undertake
experimental work to obtain parameter estimates; if these can be obtained, then we have created
a highly customisable structure which could be exploited to predict drug reservoir levels and the
impact which perturbations to drug regimens will have on this measure. Moreover, the system
lends itself well to the exploration of non-invasive extraction and drug monitoring techniques across
the skin as it describes both total amount in the SC and also spatial distribution of drug in the
SC. The first measure is relevant to extraction techniques such as reverse iontophoresis whilst the
second lends itself to the process of tape stripping.
Of course, the model has limitations. It provides a very simplified structure for drug distribution
in the body and also movement of drug in the lipid matrix of the SC. However at this stage, it still
provides useful insight into how a drug reservoir may establish depending on key drug properties
such as binding affinity. Another issue may be interpatient variability such as age and ethnicity
which could be incorporated by careful modification of ’average’ model parameter estimates once
such data sources are available.
In the meantime, we believe that the results extracted from our model analysis can contribute to
on going discussions about drug reservoirs in the skin, their dependence on the molecular properties
of those drugs and the potential to exploit these reservoirs to improve drug monitoring techniques
for chronically ill patients.
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Appendix A. Steady State Distributions in the Stratum Corneum
We define
C =

Cu
Cb
ω
 (A.1)
with ω =
dCu
dx
and use this to rewrite (3) at steady state as

C˙u
C˙b
ω˙
 =

0 0 1
γ
v
−µ
v
0
γ
D
− µ
D
v
D


Cu
Cb
ω
 (A.2)
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The eigenvalues of the system are
λ0 = 0 (A.3)
λ+ =
v
D
− µ
v
+
√(
− v
D
+
µ
v
)2
+ 4
( µ
D
+
γ
D
)
2
(A.4)
λ− =
v
D
− µ
v
−
√(
− v
D
+
µ
v
)2
+ 4
( µ
D
+
γ
D
)
2
(A.5)
with corresponding eigenvectors
v0 =

µ
γ
1
0
 , v+ =

µ+ λ+v
γ
1
λ+µ+ λ+2v
γ
 , v− =

µ+ λ−v
γ
1
λ−µ+ λ−2v
γ
 (A.6)
Appendix B.
17
P
ar
am
et
er
D
es
cr
ip
ti
on
R
an
ge
V
al
ue
us
ed
C
al
cu
la
ti
on
R
el
ev
an
t
da
ta
w
/
re
fe
re
nc
es
in
nu
m
er
ic
s
k
1
R
at
e
of
bi
nd
in
g
k
1
>
>
k
2
10
00
of
bu
p
in
pl
as
m
a
(h
−
1
)
k
2
R
at
e
of
m
ov
em
en
t
be
tw
ee
n
pl
as
m
a
k
2
>
k
3
,
0.
5
an
d
w
el
l
pe
rf
us
ed
ti
ss
ue
s
(h
−
1
)
k
3
R
at
e
of
m
ov
em
en
t
be
tw
ee
n
pl
as
m
a
k
2
>
k
3
,
0.
1
an
d
po
or
ly
pe
rf
us
ed
ti
ss
ue
s
(h
−
1
)
k
4
R
at
e
of
ex
cr
et
io
n
of
bu
p
(h
−
1
)
0.
30
M
ea
n
V
al
ue
of
el
im
in
at
io
n
ra
te
co
ns
ta
nt
es
ti
m
at
ed
fo
r
1.
2m
g
IV
[2
2]
k
5
ra
te
of
bi
nd
in
g
of
bu
p
in
10
0
w
el
l
pe
rf
us
ed
ti
ss
ue
s
(h
−
1
)
k
6
R
at
e
of
bi
nd
in
g
of
bu
p
in
10
0
po
or
ly
pe
rf
us
ed
ti
ss
ue
s
(h
−
1
)
V
m
a
x
M
ax
ve
lo
ci
ty
(m
ic
ha
el
is
m
en
te
n
82
9
82
9
0.
71
2(
V
m
ax
)
0.
71
2n
m
ol
m
in
−
1
m
g
of
pr
ot
ei
n−
1
[2
3]
ki
ne
ti
cs
fo
r
bu
p
m
et
ab
ol
is
m
)
x
32
(M
P
P
G
L
)
M
P
P
G
L
=
32
m
g
/
g
[2
4]
(µ
m
ol
l−
1
h
−
1
)
x1
82
0(
liv
er
w
ei
gh
t)
liv
er
w
ei
gh
t=
2.
6%
of
B
W
[2
5]
x
60
(m
in
−
>
hr
)
70
kg
hu
m
an
x
10
−
9
(n
m
ol
)
/3
L
(p
la
sm
a
vo
l)
(3
.6
2-
4.
04
x
10
3
)
(3
.1
4
±
0.
03
3n
m
m
in
−
1
m
gp
ro
te
in
−
1
[2
6]
)
k
m
M
ic
ha
el
is
ra
te
co
ns
ta
nt
fo
r
bu
p
39
.3
±9
.2
39
.3
39
.3
±
9.
2µ
M
ol
a
r[
23
]
(µ
m
ol
l−
1
)
(8
5
±
16
)
(
85
±
16
µ
M
ol
a
r[
26
])
f u
p
Fr
ac
ti
on
of
bu
p
in
pl
as
m
a
un
bo
un
d
0.
04
0.
04
-
[2
7]
f u
q
Fr
ac
ti
on
of
bu
p
in
w
el
l
pe
rf
us
ed
ti
ss
ue
s
th
at
is
un
bo
un
d
[0
,1
]
0.
04
se
e
te
xt
f u
r
Fr
ac
ti
on
of
bu
p
in
po
or
ly
pe
rf
us
ed
ti
ss
ue
s
th
at
is
un
bo
un
d
[0
,1
]
0.
04
se
e
te
xt
f 2
R
at
io
of
un
bo
un
d
bu
p
be
tw
ee
n
pl
as
m
a
an
d
w
el
l
f 2
>
f 3
0.
5
se
e
te
xt
pe
rf
us
ed
ti
ss
ue
s
at
eq
ui
lib
ri
um
f 3
R
at
io
of
un
bo
un
d
bu
p
be
tw
ee
n
pl
as
m
a
an
d
po
or
ly
f 2
>
f 3
0.
2
se
e
te
xt
pe
rf
us
ed
ti
ss
ue
s
at
eq
ui
lib
ri
um
k
ab
so
rp
ti
on
co
ns
ta
nt
(h
−
1
)
2.
5
δ
Su
bl
in
gu
al
do
se
of
bu
p
do
se
(m
g)
x
0.
33
94
0.
43
1
d
o
se
x
b
io
a
v
a
il
a
b
il
it
y
M
x
p
la
sm
a
v
o
l
su
bl
in
gu
al
bi
oa
va
lia
bi
lit
y=
50
%
[2
8]
(µ
m
ol
l−
1
)
m
ol
ar
m
as
s
(M
)=
46
7.
64
In
tr
av
en
ou
s
do
se
of
bu
p
do
se
(m
g)
x
0.
67
89
pl
as
m
a
vo
l=
3.
15
L
[1
2]
V
Q
/
P
ra
ti
o
of
vo
lu
m
es
of
w
el
l
pe
rf
us
ed
3.
18
10
.0
31
/3
.1
5
V
Q
=
10
.0
31
L
[1
2,
29
]
ti
ss
ue
an
d
pl
as
m
a
co
m
pa
rt
m
en
ts
V
R
/
P
ra
ti
o
of
vo
lu
m
es
of
po
or
ly
pe
rf
us
ed
17
.6
55
.5
1/
3.
15
V
R
=
55
.5
1
L
[1
2,
29
]
ti
ss
ue
an
d
pl
as
m
a
co
m
pa
rt
m
en
ts
T
a
b
le
B
.1
:
p
a
ra
m
et
er
s
a
n
d
th
ei
r
es
ti
m
a
te
s
a
lo
n
g
w
it
h
ca
lc
u
la
ti
o
n
s
a
n
d
a
p
p
ro
p
ri
a
te
d
a
ta
so
u
rc
es
.
18
[1] M. S. Roberts, S. E. Cross, and Y. G. Anissimov, “Factors affecting the formation of a skin
reservoir for topically applied solutes,” Skin Pharmacology and Physiology, vol. 17, pp. 3–16,
2004.
[2] C. H. Vickers, “Existence of reservoir in the stratum corneum: Experimental proof,” Archives
of Dermatology, vol. 88, no. 1, pp. 20–23, 1963.
[3] R. D. Carr and R. G. Wieland, “Corticosteroid reservoir in the stratum corneum,” Archives
of Dermatology, vol. 94, no. 1, pp. 81–84, 1966.
[4] C. H. Vickers, “Stratum corneum reservoir for drugs,” Advances in Biology of Skin, vol. 12,
pp. 177–189, 1972.
[5] J. M. Nitsche and H. F. Frasch, “Dynamics of diffusion with reversible binding in microscop-
ically heterogeneous membranes: General theory and applications to dermal penetration,”
Chemical Engineering Science, vol. 66, no. 10, pp. 2019 – 2041, 2011.
[6] M. B. Reddy, R. H. Guy, and A. L. Bunge, “Does epidermal turnover reduce percutaneous
penetration?,” Pharmaceutical Research, vol. 17, no. 11, pp. 1414–1419, 2000.
[7] S. Seif and S. Hansen, “Measuring the stratum corneum reservoir: Desorption kinetics from
keratin,” Journal of Pharmaceutical Sciences, vol. 101, pp. 3718–3728, 2012.
[8] B. Leboulanger, J. Aubry, G. Bondolfi, R. H. Guy, and B. M. Delgado-Charro, “Lithium
monitoring by reverse iontophoresis in vivo,” Clinical Chemistry, vol. 50, no. 11, pp. 2091–
2100, 2004.
[9] B. Leboulanger, M. Fathi, R. Guy, and B. M. Delgado-Charro, “Reverse iontophoresis as a non-
invasive tool for lithium monitoring and pharmacokinetic profiling,” Pharmaceutical Research,
vol. 21, no. 7, pp. 1214–1222, 2004.
[10] Y. Paulley, M. B. Delgado-Charro, and K. A. J. White, “Modelling formation of a drug reservoir
in the stratum corneum and its impact on drug monitoring using reverse iontophoresis.,”
Computational and Mathematical Methods in Medicine, vol. 11, no. 4, p. 353, 2010.
[11] A. Rostami-Hodjegan, “Physiologically based pharmacokinetics joined with in vitro- in vivo
extrapolation of adme: A marriage under the arch of systems pharmacology,” Clinical Phar-
macology and Therapeutics, vol. 92, no. 1, 2012.
[12] A. Paradkar, Biopharmaceutics & Pharmacokinetics, ch. 3. Pragati Books, 2008.
[13] Modeling in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics: Homogeneous and
Heterogeneous Approaches. Springer Science and Business Media, Inc., New York, 2006.
[14] Y. G. Anissimov and M. S. Roberts, “Diffusion modelling of percutaneouos absorption ki-
netics:4. effects of a slow equilibration process within stratum corneum on absorption and
desorption kinetics,” Journal of Pharmaceutical Sciences, vol. 98, pp. 772–781, 2008.
[15] A. C. Williams, Transdermal and Topical Drug Delivery. Pharmaceutical Press, 2003.
19
[16] L. Jansen, M. Hojyotom, and A. Kligman, “Improved fluorescence staining technique for esti-
mating turnover of human stratum-corneum,” British Journal of Dermatology, vol. 90, no. 1,
pp. 9–12, 1974.
[17] L. Simon, K. Kwang, and K. Kanneganti, “Effects of epidermal turnover on the dynamics of
percutaneous drug absorption,” Mathematical Biosciences, vol. 229, pp. 16–21, 2011.
[18] J. Sandby-Moller, T. Poulsen, and H. C. Wulf, “Epidermal thickness at different body sites:
Relationship to age, gender, pigmentation, blood content, skin type and smoking habits,” Acta
Dermato- Venereologica, vol. 83, pp. 410–413, 2003.
[19] S. Rotheberg, R. Crounse, and J. Lee, “Glycine-c-14 incorporation into the proteins of normal
stratum corneum and the abnormal stratum corneum of psoriasis,” Journal of Investigative
Dermatology, vol. 37, no. 6, pp. 497–505, 1961.
[20] G. Weinstei and E. Vanscott, “Autoradiographic analysis of turnover times of normal and
psoriatic epidermis,” Journal of Investigative Dermatology, vol. 45, no. 4, p. 257, 1965.
[21] G. Pontrelli and F. de Monte, “A two-phase two-layer model for transdermal drug delivery,”
Mathematical Biosciences, vol. 257, pp. 96–103, 2014.
[22] J. J. Kuhlman, S. Lalani, J. Magluilo, B. Levine, W. D. Darwin, R. E. Johnson, and E. J. Cone,
“Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine,” Journal of
Analytical Toxicology, vol. 20, pp. 369–378, 1996.
[23] K. Kobayashi, T. Yamamoto, K. Chiba, M. Tani, N. Shimada, T. Ishizaki, and Y. Kuroiwa,
“Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4,” Drug
Metabolism and Disposition, vol. 26, no. 8, pp. 818–821, 1998.
[24] Z. E. Barter, J. E. Chowdry, J. R. Harlow, J. E. Snawder, J. C. Lipscomb, and A. Rostami-
Hodjegan, “Covariation of human microsomal protein per gram of liver with age: Absence
of influence of operator and sample storage may justify interlaboratory data pooling,” Drug
Metabolism and Disposition, vol. 36, no. 12, pp. 2405–2409, 2008.
[25] G. L. Kedderis and S. D. Held, “Prediction of furan pharmacokinetics from hepatocyte studies:
Comparison of bioactivation and hepatic dosimetry in rats, mice, and humans,” Toxicology and
Applied Pharmacology, vol. 140, no. 1, pp. 124 – 130, 1996.
[26] C. Iribarne, D. Picart, Y. Dreano, J.-P. Bail, and F. Berthou, “Involvement of cytochrome P450
3A4 in N-dealkylation of buprenorphine in human liver microsomes,” Life Sciences, vol. 60,
no. 22, pp. 1953–1964, 1997.
[27] R. Heel, R. Brogden, T. Speight, and G. Avery, “Buprenorphine: A review of its pharmaco-
logical properties and therapeutic efficacy,” Drugs, vol. 17, no. 2, pp. 81–110, 1979.
[28] R. P. Nath, R. A. Upton, E. T. Everhart, P. Cheung, P. Shwonek, R. T. Jones, and J. E.
Mendelson, “Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tablet
and liquid formulations,” The Journal of Clinical Pharmacology, vol. 39, pp. 619–623, 1999.
20
[29] P. Poulin and S. Haddad, “Advancing prediction of tissue distribution and volume of distri-
bution of highly lipophilic compounds from a simplified tissue-composition-based model as a
mechanistic animal alternative method,” Journal of Pharmaceutical Sciences, vol. 101, no. 6,
pp. 2250–2261, 2012.
21
